ClinicalTrials.gg
CompletedNCT02852967Updated Mar 16, 2022Results posted

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

A Phase 2 interventional study of Belumosudil and Placebo in Chronic Plaque Psoriasis, sponsored by Kadmon Corporation, LLC. Completed at 14 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Enrollment
84th of 172
110 · median 99
Started
2016
with 9 others
Phase 2
63 of 202
8 open now
Registered
65th of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 84th largest by enrollment of the 172 interventional ones that give a count, is one of 10 that started in 2016, is one of 63 in phase 2, and was the 65th registered.

Skin Diseases

497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Read the detailed description

This phase 2, two-period, dose-finding, placebo-controlled study is performed on adult male and female subjects to evaluate the efficacy and safety of subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Period 1: Double-blind, Placebo-controlled Treatment Period

Approximately 110 subjects are planned to be randomly assigned to each of 5 dose cohorts in a 1:1:1:1:1 manner. Each cohort is planned to have 22 subjects who meet eligibility criteria. Subjects are treated with oral (PO) belumosudil tablets or placebo tablets as follows:

  • 200 mg belumosudil once daily (QD) (Cohort 1) = one 200 mg belumosudil tablet and 1 matching placebo in the morning and 1 matching placebo in the evening
  • 200 mg belumosudil twice daily (BID) (Cohort 2) = one 200 mg belumosudil tablet in the morning and one matching placebo in the morning, and one 200 mg belumosudil tablet in the evening
  • 400 mg belumosudil QD (Cohort 3) = two 200 mg belumosudil tablets in the morning and one matching placebo in the evening
  • 600 mg/day belumosudil (Cohort 4) = two 200 mg belumosudil tablets in the morning and one 200 mg belumosudil tablet in the evening
  • Matching placebo BID (Cohort 5) = 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening

Subjects in each of the 5 cohorts in Period 1 are treated with study medication for a period of 16 weeks.

Note: Originally, a sample size of 36 subjects per cohort was planned to provide approximately 90% probability ≥ 1 subject in the 5 cohorts would experience an adverse event (AE) that had an underlying rate of ≥ 6% and approximately an 80% probability of ≥ 1 subject in the cohort experiencing an AE that had an underlying rate of ≥ 4%. However, due to a newly available plaque psoriasis treatment, the study is terminated early with 110 subjects.

Period 2: Open-label Treatment Period (with Belumosudil)

All subjects treated for 16 weeks, regardless of treatment with belumosudil (Cohorts 1 through 4) or placebo (Cohort 5) are given the option to receive 400 mg belumosudil QD for an additional 32 weeks (Week 16 through Week 48).

Follow-up Period

All subjects have a safety evaluation 30 days after the last dose of study drug.

Efficacy is assessed by the following scores at scheduled time points throughout the study:

  • Psoriasis Area and Severity Index (PASI): Measure of psoriasis disease severity using average redness, thickness, and scaliness of lesions (each lesion graded 0 to 4), combined into single score ranging on a scale from 0 (no disease) to 72 (maximum disease)
  • Physician's Global Assessment (PGA): Physician's assessment of a subject's psoriasis, relative to baseline, ranging on a scale from 1 (100% clearing of psoriasis) to 6 (poor to no clearing)
  • Dermatology Life Quality Index (DLQI): Skin disease-specific instrument for assessing impact of disease on subject's quality of life ranging on a scale from 0 (no effect on subject's life) to 30 (extremely large effect on subject's life)

Safety is assessed by;

  • AEs and serious AE (SAEs)
  • Physical examination
  • Vital sign measurements
  • Clinical laboratory evaluations
  • Electrocardiogram
  • Reasons for discontinuation due to toxicity analyses

The maximum duration for subjects who complete Period 1 (Double-blind, Placebo-controlled) is 24 weeks (up to 4-week Screening, 16-week Period 1 treatment, and 4-week Follow-up). The maximum duration for subjects who complete Period 2 (Open-label) is 56 weeks (up to 4-week Screening, 16-week Double-blind Treatment Period, 32-week Open-label Treatment Period, and 4-week Follow-up).

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Skin Diseases
  • Auto-Immune Diseases
  • Plaque
  • Dermatology
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects between the ages of 18 and 65 years
  • Able to provide written Form prior to the performance of any study-specific procedures
  • Diagnosis of moderate to severe chronic plaque psoriasis and a candidate for systemic therapy or phototherapy
  • PASI of ≥ 12 at screening and prior to the first dose of study drug, confirmed at Week 1 Day 1 (Baseline)
  • ≥ 10% PASI body surface area involvement at screening and prior to the first dose of study drug, confirmed at Baseline
  • Willing to avoid tanning devices
  • Adequate bone marrow function:

    • > 1500/mm\^3
    • > 9.0 g/dL
    • > 100,000/mm\^3
  • Adequate safety laboratory values:

    • Serum total within normal limits (WNL)
    • (AST) and alalnine aminotransferase (ALT) \< 2 × (ULN)
    • Serum creatinine \< 1.5 × ULN
  • Female subjects of with a negative pregnancy test at screening. Females of childbearing potential were defined as sexually mature women without prior hysterectomy or who had any evidence of menses in the past 12 months. However, women who had been amenorrheic for 12 or more months were still considered to be of childbearing potential if the amenorrhea was possibly due to prior chemotherapy, antiestrogens, or ovarian suppression

    • Women of childbearing potential (i.e., menstruating women) had to have a negative urine pregnancy test (positive urine tests were to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug
    • Sexually active women of childbearing potential enrolled in the study had to agree to use 2 forms of accepted methods of during the course of the study and for 3 months after their last dose of study drug. Effective birth control included: (a) intrauterine device plus 1 barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; and (c) 2 barrier methods. Effective barrier methods were male or female condoms, diaphragms, and spermicides (creams or gels that contained a chemical to kill sperm); or (d) a vasectomized partner
  • For male patients who were sexually active and who were partners of premenopausal women: agreed to use 2 forms of contraception as defined above during the treatment period and for at least 3 months after the last dose of study drug
  • Willing to complete all study measurements and assessments in compliance with the protocol

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug-induced (antimalarials, lithium) psoriasis (If subject was taking angiotensin II receptor blockers or beta blockers doses must have been stable for 6 months prior to study entry)
  • Used systemic within 12 weeks prior to study entry
  • Used topical corticosteroids except to the face, groin, or scalp
  • Used methotrexate, retinoids (such as acitretin), or calcineurin inhibitors (such as cyclosporine) within 4 weeks prior to study entry
  • Phototherapy within 4 weeks prior to study entry
  • Biologic therapies, including antibodies to IL-17; anti-tumor necrosis factor-alpha; and anti-IL-12 \& IL-23 within 3 months prior to study entry
  • Current use of an inhibitor or inducer of
  • Active viral, fungal, or bacterial skin infection (other than nail fungal infection).
  • Pregnant or lactating woman
  • History of gastrointestinal (GI) surgery including any bariatric surgery, or any GI condition that might interfere with drug absorption
  • Participating in another study with an drug or within 28 days or 5 half-lives of the investigational drug (whichever was longer) of study entry
  • History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the investigator, unsuitable for the study
  • Regular and/or excessive use of alcohol within 2 years prior to study entry defined as alcohol intake > 14 drinks per week in a man or > 7 drinks per week in a woman. Approximately 10 g of alcohol equaled one "drink" unit. One unit equaled 1 ounce of distilled spirits, one 12-ounce beer, or one 4-ounce glass of wine
  • data corrected using Fridericia's formula (QTcF) > 450 msec (average of 3 readings) during screening
  • Exposure to belumosudil or known allergy/sensitivity to belumosudil within the last 6 months prior to study entry or any other ROCK-2 inhibitor
  • History or presence of any of the following:

    • or AST > 2.0 × at screening
    • Renal disease and/or serum creatinine > 1.5 × ULN at screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Belumosudil 200 mg QD + Placebo

    One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening

    Drug: Belumosudil · Drug: Placebo

  • Experimental
    Belumosudil 200 mg BID (Twice Daily) + Placebo

    One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening

    Drug: Belumosudil · Drug: Placebo

  • Experimental
    Belumosudil 400 mg QD + Placebo

    Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening

    Drug: Belumosudil · Drug: Placebo

  • Experimental
    Belumosudil 600 mg/day

    Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening

    Drug: Belumosudil

  • Placebo comparator
    Placebo

    Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening

    Drug: Placebo

Interventions

  • Also known as: Rezurock (brand name), KD025

  • DrugPlacebo

    Placebo tablets matching belumosudil

06

What researchers measure

Primary outcomes

  1. Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed

    The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward \[LOCF\]) and those who did complete 16 weeks of treatment (observed). \[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 16 weeks

Secondary outcomes

  1. Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed

    The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 48 weeks

  2. Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed

    The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]) or for only those subjects who completed 16 and 48 weeks (observed), respectively. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

    Time frame: 48 weeks

  3. Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF

    The number of subjects who had a "Clear" or "Almost Clear" assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]) \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]

    Time frame: 16 weeks

  4. Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF

    The percentage (%) of subjects who had a "Clear" or "Almost Clear" assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]). \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]

    Time frame: 16 weeks

  5. Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48

    Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change \< 0% is improvement; \> 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]

    Time frame: Up to 48 weeks

  6. Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48

    Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]

    Time frame: Up to 48 weeks

  7. Safety: Number of Subjects With TEAEs, SAEs, and Deaths Throughout the Study

    The number of subjects who had treatment-emergent adverse events (TEAEs), severity of TEAEs, relationship of TEAEs to study medication, serious TEAEs (SAEs), dose interruption, discontinuations, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = Death. Related to study medication is defined as possible related, probable related, and related

    Time frame: Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up

07

Results

Posted Sep 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlacebo
Started2322212618
Completed period 1: double-blind1415171610
Completed period 2: open-label118131114
Completed96942
Not completed1416122216
Withdrew: Adverse event31010
Withdrew: Death10000
Withdrew: Lost to follow-up12344
Withdrew: Withdrawal by subject61271010
Withdrew: Sae00030
Withdrew: Elevated liver enzymes20022
Withdrew: Physician decision00010
Withdrew: Lack of efficacy01000
Withdrew: Non-compliance00110
Withdrew: Dispensing drug violation00100
Withdrew: Inclusion/exclusion violation10000

Outcome measures

PrimaryEfficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed

The percentage of subjects who exhibited a 75% decrease or greater in the Psoriasis Area and Severity Index Score (PASI 75) whether they completed 16 weeks of treatment or not (last observation carried forward \[LOCF\]) and those who did complete 16 weeks of treatment (observed). \[PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
16 weeks
Reported as:
Number · Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed
Percentage of participantsBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
LOCF (%)8.7 (1.1 to 28.0)9.1 (1.1 to 29.2)19.0 (5.4 to 41.9)7.7 (0.9 to 25.1)16.7 (3.6 to 41.4)10.9 (5.3 to 19.1)
Observed (%)7.1 (0.2 to 33.9)13.3 (1.7 to 40.5)23.5 (6.8 to 49.9)12.5 (1.6 to 38.3)30.0 (6.7 to 65.2)14.5 (6.9 to 25.8)
Statistical analysis
  • Belumosudil 200 mg QD + Placebo · Fisher Exact · p = 0.6384
  • Belumosudil 200 mg BID (Twice Daily) + Placebo · Fisher Exact · p = 0.6419
  • Belumosudil 400 mg QD + Placebo · Fisher Exact · p = > 0.9999
  • Belumosudil 600 mg/Day · Fisher Exact · p = 0.3859
  • All Belumosudil · Fisher Exact · p = 0.4435
  • Belumosudil 200 mg QD + Placebo · Fisher Exact · p = 0.2721
  • Belumosudil 200 mg BID (Twice Daily) + Placebo · Fisher Exact · p = 0.3577
  • Belumosudil 400 mg QD + Placebo · Fisher Exact · p = > 0.9999
  • Belumosudil 600 mg/Day · Fisher Exact · p = 0.3402
  • All Belumosudil · Fisher Exact · p = 0.3542
SecondaryEfficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed

The mean change in the raw Psoriasis Area and Severity Index (PASI) score from baseline score to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]), or for only those subjects who completed 16 and 48 weeks (observed), respectively. Negative values represent favorable results; positive values represent unfavorable results. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
48 weeks
Reported as:
Mean · Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and Observed
Score on a scaleBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
Baseline18.93 ± 8.3120.60 ± 8.2718.82 ± 6.0819.80 ± 9.0320.72 ± 8.0819.55 ± 7.97
Change at Week 16--LOCF-5.69 ± 8.59-4.49 ± 7.44-5.0 ± 8.31-4.63 ± 8.04-5.68 ± 12.31-4.96 ± 7.98
Change at Week 16--Observed-3.75 ± 8.62-6.29 ± 6.45-4.96 ± 8.72-3.81 ± 5.37-8.44 ± 15.36-4.71 ± 7.31
Change at Week 48--LOCF-3.85 ± 10.53-6.38 ± 5.16-9.01 ± 7.63-0.83 ± 7.73-9.56 ± 18.98-5.11 ± 8.45
Change at Week 48--Observed-5.93 ± 11.26-5.30 ± 5.88-12.99 ± 6.71-4.27 ± 2.169.45 ± 21.00-7.98 ± 8.76
SecondaryEfficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed

The percentage (%) change in the mean Psoriasis Area and Severity Index (PASI) score from baseline ore to Week 16 and to Week 48 whether the subject completed 16 and 48 weeks, respectively (last observation carried forward \[LOCF\]) or for only those subjects who completed 16 and 48 weeks (observed), respectively. \[The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.\]

Time frame:
48 weeks
Reported as:
Mean · Percentage Change in PASI Score
Efficacy: Percentage Change in Mean PASI Score From Baseline to Week 16 and to Week 48--LOCF and Observed
Percentage Change in PASI ScoreBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
Change (%) at Week 16--LOCF-27.17 ± 37.60-19.61 ± 35.60-24.31 ± 42.74-20.07 ± 31.20-18.23 ± 43.93-22.78 ± 36.27
Change (%) at Week 16--Observed-15.21 ± 36.90-29.70 ± 30.72-24.17 ± 44.61-20.22 ± 30.16-25.09 ± 54.31-22.46 ± 35.77
Change (%) at Week 48--LOCF-12.82 ± 40.33-30.75 ± 24.51-46.97 ± 39.90-9.31 ± 41.28-19.89 ± 90.61-25.54 ± 39.87
Change (%) at Week 48--Observed-21.81 ± 38.75-30.02 ± 34.39-63.04 ± 29.04-33.16 ± 15.4884.98 ± 166.19-38.33 ± 36.22
SecondaryEfficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF

The number of subjects who had a "Clear" or "Almost Clear" assessment, using the Physician Global Assessment Scale (PGA), at Week 16 of all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]) \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF
ParticipantsBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
Efficacy: Number of Subjects With Clear or Almost Clear PGA at Week 16--LOCF102124
SecondaryEfficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF

The percentage (%) of subjects who had a "Clear" or "Almost Clear" assessment using the Physician Global Assessment Scale at Week 16 of belumosudil vs. placebo for all subjects whether they completed 16 weeks or not (last observation carried forward \[LOCF\]). \[The PGA documents the physician's assessment of the subject's psoriasis and was assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.\]

Time frame:
16 weeks
Reported as:
Number · Percentage (%) of subjects
Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF
Percentage (%) of subjectsBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayAll Belumosudil
Efficacy: Percentage of Subjects With Clear or Almost Clear PGA Comparing Belumosudil to Placebo at Week 16--LOCF-6.8 (-23.5 to 10.0)-11.1 (-25.6 to 3.4)-1.6 (-20.8 to 17.6)-7.3 (-23.6 to 9.0)-6.8 (-21.9 to 8.3)
Statistical analysis
  • Belumosudil 200 mg QD + Placebo · Fisher Exact · p = 0.5728
  • Belumosudil 200 mg BID (Twice Daily) + Placebo · Fisher Exact · p = 0.1962
  • Belumosudil 400 mg QD + Placebo · Fisher Exact · p = > 0.9999
  • Belumosudil 600 mg/Day · Fisher Exact · p = 0.5583
  • All Belumosudil · Fisher Exact · p = 0.2538
SecondaryEfficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48

Changes in mean Dermatology Life Quality Index (DLQI) score from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. DLQI scoring as measured on subject's life: 0-1 = no effect; 2-5 = small effect; 6-10 = moderate effect; 11 to 20 = very large effect; 21 to 30 = extremely large effect. Change \< 0% is improvement; \> 0% is worsening. The total rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]

Time frame:
Up to 48 weeks
Reported as:
Mean · Score on a scale
Efficacy: Change in Mean DLQI Raw Score at Week 16 and at Week 48
Score on a scaleBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
Baseline10.6 ± 6.316.5 ± 9.412.2 ± 6.511.0 ± 7.110.3 ± 6.412.5 ± 7.7
Change at Week 16-2.2 ± 5.6-3.4 ± 4.0-2.5 ± 6.0-2.3 ± 7.0-4.0 ± 6.7-2.6 ± 5.7
Change at Week 48-6.5 ± 5.1-1.0 ± 8.6-5.2 ± 6.9-3.7 ± 3.2-3.0 ± 2.8-4.7 ± 6.3
SecondaryEfficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48

Mean percentage changes in Dermatology Life Quality Index (DLQI) from baseline at Week 16 (End of Double-blind Period) and at Week 48 (End of Study Treatment). \[The DLQI is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The rating ranges from 0 (no effect on a subject's life) to 30 (extremely large effect on a subject's life.\]

Time frame:
Up to 48 weeks
Reported as:
Mean · Percentage change of DLQI score
Efficacy: Percentage Change of Mean DLQI Score From Baseline to Week 16 and Week 48
Percentage change of DLQI scoreBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
Percentage Change at Week 16-5.73 ± 60.75-14.8 ± 28.78-22.22 ± 48.60-6.4 ± 79.95-40.30 ± 47.83-12.55 ± 56.58
Percentage Change at Week 48-32.41 ± 86.973.54 ± 54.32-45.60 ± 45.84-53.73 ± 45.24-54.17 ± 41.25-33.11 ± 65.64
SecondarySafety: Number of Subjects With TEAEs, SAEs, and Deaths Throughout the Study

The number of subjects who had treatment-emergent adverse events (TEAEs), severity of TEAEs, relationship of TEAEs to study medication, serious TEAEs (SAEs), dose interruption, discontinuations, and deaths. Treatment-emergent adverse events (TEAEs) are AEs that are not present before the first dose of IMP or that are present before the first dose of IMP but worsen in intensity during exposure to IMP. Severity: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = Death. Related to study medication is defined as possible related, probable related, and related

Time frame:
Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up
Reported as:
Count of participants · Participants
Safety: Number of Subjects With TEAEs, SAEs, and Deaths Throughout the Study
ParticipantsBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudile
At least 1 TEAE141314161157
Grade 3 or Greater TEAE2305210
Related TEAE8659628
Related Grade 3 or Greater TEAE110315
Leading to Dose Interruption111407
SAE100314
Related SAE000000
Leading to Discontinuation6117315
Deaths100001

Adverse events

Collected over Approximately 52 weeks: up to 48 weeks of treatment and 30-day follow-up. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belumosudil 200 mg QD + Placebo1/23 (4.3%)1/23 (4.3%)14/23 (60.9%)
Belumosudil 200 mg BID (Twice Daily) + Placebo0/22 (0%)0/22 (0%)13/22 (59.1%)
Belumosudil 400 mg QD + Placebo0/21 (0%)0/21 (0%)14/21 (66.7%)
Belumosudil 600 mg/Day0/26 (0%)3/26 (11.5%)16/26 (61.5%)
Placebo0/18 (0%)1/18 (5.6%)11/92 (12%)
All Belumosudil1/92 (1.1%)1/92 (1.1%)57/92 (62%)
Most frequent serious events
Most frequent serious events
EventBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
HypercholesterolemiaMetabolism and nutrition disorders0/230/220/210/261/181/92
Natural deathGeneral disorders1/230/220/210/260/181/92
Chronic obstructive pulmonary disease (COPD)Respiratory, thoracic and mediastinal disorders0/230/220/211/260/181/92
PneumoniaInfections and infestations0/230/220/211/260/180/92
Thalamic infarctionNervous system disorders0/230/220/211/260/181/92
Most frequent other events
Showing 10 of 27
Most frequent other events
EventBelumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboAll Belumosudil
NauseaGastrointestinal disorders0/234/221/211/261/926/92
InfluenzaInfections and infestations0/231/223/210/260/924/92
Viral upper respiratory tract infectionInfections and infestations2/233/220/211/260/926/92
Urinary tract infectionInfections and infestations0/230/222/211/261/923/92
HeadacheNervous system disorders0/232/222/212/260/926/92
PruritusSkin and subcutaneous tissue disorders0/231/222/211/261/924/92
DyspepsiaGastrointestinal disorders0/232/220/210/260/922/92
ContusionInjury, poisoning and procedural complications0/232/220/210/260/922/92
Alanine aminotransaminase (ALT) increasedInvestigations2/230/221/212/262/925/92
Hepatic enzyme increasedInvestigations2/231/220/212/261/925/92

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboTotal
Mean49.3 ± 8.946.2 ± 9.643.0 ± 11.443.5 ± 11.545.7 ± 14.245.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Belumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboTotal
Female161314151169
Male79711741
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboTotal
Hispanic or Latino5448223
Not Hispanic or Latino181816181585
Unknown or Not Reported001012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboTotal
American Indian or Alaska Native001001
Asian211004
Native Hawaiian or Other Pacific Islander000101
Black or African American112138
White201917241494
More than one race000000
Unknown or Not Reported010012
BMI (Mean)
BMI (Mean)(kg/m^2)Belumosudil 200 mg QD + PlaceboBelumosudil 200 mg BID (Twice Daily) + PlaceboBelumosudil 400 mg QD + PlaceboBelumosudil 600 mg/DayPlaceboTotal
Mean33.8 ± 9.930.7 ± 7.029.9 ± 7.433.1 ± 10.732 ± 6.732.0 ± 8.7
08

Study locations

14 sites
  • Alliance Dermatology and Mohs Center
    Phoenix, Arizona 85032, United States
  • University of California, Irvine - Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Dawes Fretzin Dermatology Group
    Indianapolis, Indiana 46256, United States
  • Dermatology Specialists Research
    New Albany, Indiana 40202, United States
  • Dermatology Specialists Research
    Louisville, Kentucky 40202, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Suzanne Bruce and Associates
    Katy, Texas 77056, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Feb 2019, 28 months.

Results were first posted in Sep 2021, 2 years 7 months after primary completion. A results delay was requested in Apr 2020.

Of 42 industry-sponsored phase 2 interventional studies under Skin Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 19. This study's 28 months is above that.

Counting every sponsor, half of 57 studies reached it within 15 months; a quarter within 10 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2016
First posted
Aug 2, 2016
StartActual
Sep 14, 2016
Primary completionActual
Feb 13, 2019
CompletionActual
Feb 13, 2019
Results delay requested
Apr 20, 2020
Results first posted
Sep 13, 2021
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02852967
Responsible party
Sponsor
First posted
Aug 2, 2016
Start date
Sep 14, 2016
Primary completion
Feb 13, 2019
Completion
Feb 13, 2019
Results posted
Sep 13, 2021
Last update
Mar 16, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion